The National Institutes of Health (NIH) said this week that care for chronic obstructive pulmonary disease (COPD) is expected to cost the United States $49 billion by 2020, as it recapped its research portfolio to mark World COPD Day 2018.
The National Institutes of Health (NIH) said this week that care for chronic obstructive pulmonary disease (COPD) is expected to cost the United States $49 billion by 2020, as it recapped its research portfolio to mark World COPD Day 2018.
In the United States, 16 million people have COPD, killing more than 150,000 people each year. Millions more are believed to have COPD and not know it, as COPD symptoms develop slowly and worsen over time, the NIH said.
Delays in getting care leads to more aggressive treatment or hospitalization, the NIH said. Scientists are continuing their research on a tool, called CAPTURE, which is a simple questionnaire and breathing test to help healthcare providers identify people at risk for developing COPD before their symptoms worsen.
In addition, NIH’s National Heart, Lung, and Blood Institute (NHLBI) created a program called COPD Learn More Breathe Better to work with healthcare providers to facilitate discussions with patients to make earlier diagnosis more possible. The program seeks to increase awareness of COPD, increase understanding that COPD is treatable, and encourage people at risk to get a simple breathing test and talk to their healthcare provider about treatment options. The program targets people over age 35, especially those who smoke or have smoked, and those with risks associated with genetics or environmental exposures. Smoking accounts for 75% of COPD cases; secondhand smoke, environmental pollutants, and genetic factors also play a role.
There are 3 trials that have increased knowledge about COPD, the NIH said:
In addition, NIH studies are exploring the effectiveness of various pneumococcal vaccines; the usefulness of azithromycin in reducing the severity and occurrence of COPD exacerbations; and the role statin drugs might play in preventing or eliminating those exacerbations. Also, the COPDGene Study is investigating why some smokers develop COPD while others do not.
Other studies are evaluating how various medications affect the treatment of COPD, or to find out if a weight loss and physical activity can improve COPD symptoms for those with a high body mass index (BMI). In addition, last year, the NIH developed the COPD National Action Plan to guide care for COPD patients and other stakeholders.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Homelessness Compounds Hospital Stay Challenges: Study Reveals Prolonged Discharge Struggles
March 28th 2024In this investigation, outcomes of interest were morbidity rate and length of hospital stay or a traumatic injury among a homeless population, and whether age and/or injury severity had an influence on that relationship—with implications for improving the discharge process for these patients.
Read More
FDA Approves Vadadustat for Anemia in Patients With CKD Undergoing Dialysis
March 28th 2024The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment option as anemia is common in these patients and can significantly impact their quality of life.
Read More